# US 2021/0340631 A1 · Methods for subtyping of lung squamous cell carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340631 A1
- Document ID: US20210340631A1
- Status: Published application
- Kind: A1
- Application number: 17/323,429
- Filed: 2021-05-18
- Published: 2021-11-04
- Earliest claimed: 2016-05-17
- Assignees: GeneCentric Therapeutics, Inc.; The University of North Carolina at Chapel Hill
- Applicants: GeneCentric Therapeutics, Inc.; The University of North Carolina at Chapel Hill
- Inventors: Hawazin FARUKI; Myla LAI-GOLDMAN; Greg MAYHEW; Jonathan SERODY; Charles PEROU; David Neil HAYES
- Web page: https://patentgrep.com/patent/US20210340631A1

## CPC

- C07K 14/81: Protease inhibitors
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 9/00: Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method of assaying a lung sample obtained from a human patient, the method comprising measuring in a lung sample obtained from a human patient a nucleic acid expression level of a subset of biomarkers selected from the group of biomarkers consisting of serpin family B member 4 (SERPINB4), C—X—C motif chemokine ligand 1 (CXCL1), S100 calcium binding protein A9 (S100A9), S100 calcium binding protein A8 (S100A8), serpin family B member 3 (SERPINB3), EPH receptor A2 (EPHA2), S100 calcium binding protein A2 (S100A2), matrix metallopeptidase 10 (MMP10), interleukin 4 receptor (IL4R), PDZK1-interacting protein 1 (PDZK1IP1), CDK5 regulatory subunit associated protein 2 (CDK5RAP2), family with sequence similarity 125, member B (FAM125B), chaperone activity of bc1 complex-like (CABC1), ornithine decarboxylase 1 (ODC1), lipin 1 (LPIN1), WAS protein family member 1 (WASF1), ubiquitin specific peptidase 13 (isopeptidase T-3) (USP13), nucleoporin 210 (NUP210), GLI Family Zinc Finger 2 (GLI2), sperm associated antigen 5 (SPAG5), malic enzyme 1 (ME1), transaldolase 1 (TALDO1), aldo-keto reductase family 1, member C3 (AKR1C3), thioredoxin (TXN), aldehyde dehydrogenase 3 family member A1 (ALDH3A1), carbohydrate sulfotransferase 7 (CHST7), ADAM metallopeptidase domain 23 (ADAM23), tuftelin 1 (TUFT1), forkhead box E1 (FOXE1), aldehyde dehydrogenase 3 family member A2 (ALDH3A2), polyhomeotic homolog 2 (PHC2), solute carrier family 43 member 3 (SLC43A3), capping actin protein of muscle Z-line beta subunit (CAPZB), family with sequence similarity 46 member A (FAM46A), protein tyrosine phosphatase type IVA, member 2 (PTP4A2), dihydropyrimidine dehydrogenase (DPYD), tripartite motif containing 8 (TRIMS), CD47 molecule (CD47), cysteine rich protein 2 (CRIP2), ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5), heat shock transcription factor 2 (HSF2), MARCKS like 1 (MARCKSL1), EF-hand domain family member D1 (EFHD1), choline kinase alpha (CHKA), pleckstrin homology domain containing B1 (PLEKHB1), formin binding protein 1 like (FNBP1L), zinc finger protein 239 (ZNF239), Abelson interactor 2 (ABI2), Myosin light chain 6B (MYL6B), Tubulin Tyrosine Ligase Like 4 (TTLL4), Chloride Channel Accessory 2 (CLCA2), Gap Junction Protein Beta 3 (GJB3), G Protein-Coupled Receptor 87 (GPR87), Stratifin (SFN), Cystatin A (CSTA), Desmoglein 3 (DSG3), ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 2 (ST6GALNAC2), Gap Junction Protein Beta 5 (GJB5), Transmembrane Protease, Serine 4 (TMPRSS4), Syndecan 1 (SDC1), Formin Like 1 (FMNL1), Baculoviral IAP Repeat Containing 3 (BIRC3), Rho GDP Dissociation Inhibitor Beta (ARHGDIB), SH2B Adaptor Protein 3 (SH2B3), Major Histocompatibility Complex, Class II, DP Alpha 1 (HLA-DPA1), Neutrophil Cytosolic Factor 4 (NCF4), Acyl-CoA Synthetase Long-Chain Family Member 5 (ACSL5), Colony Stimulating Factor 2 Receptor Alpha Subunit (CSF2RA), Lysosomal Protein Transmembrane 5 (LAPTM5), ADP-ribosylation-like factor 6 interacting protein 5 (ARL6IP5), Alcohol Dehydrogenase 7 (Class IV), Mu Or Sigma (ADH7), ATP Binding Cassette Subfamily C Member 5 (ABCC5), SRY-Box 2 (50×2), Solute Carrier Family 9, Subfamily A (NHE3, Cation Proton Antiporter 3), Member 3 Regulator 1 (SLC9A3R1), Kruppel-Like Factor 5 (Intestinal) (KLF5), Glutathione Peroxidase 2 (GPX2), Pirin (PIR), Tumor Protein D52-Like 1 (TPD52L1), Solute Carrier Family 6 Member 8 (SLC6A8), and Siah E3 Ubiquitin Protein Ligase 2 (SIAH2).

### Claim 29 (depends on 28)

The method of claim 28, wherein the lung sample was previously diagnosed as being squamous cell carcinoma (SCC).

### Claim 30

(canceled)

### Claim 31 (depends on 28)

The method of claim 28, wherein the measuring is performed by an amplification, hybridization and/or sequencing assay, wherein the amplification, hybridization and/or sequencing assay comprises quantitative real time reverse transcriptase polymerase chain reaction (qRT-PCR), RNAseq, microarrays, gene chips, nCounter Gene Expression Assay, Serial Analysis of Gene Expression (SAGE), Rapid Analysis of Gene Expression (RAGE), nuclease protection assays or Northern blotting.

### Claim at position 6

-33. (canceled)

### Claim 34 (depends on 28)

The method of claim 28, wherein the lung sample is a formalin-fixed, paraffin-embedded (FFPE) lung tissue sample, fresh or a frozen lung tissue sample, an exosome, wash fluids, cell pellets, or a bodily fluid obtained from the human patient.

### Claim at position 8

-78. (canceled)

### Claim 79

A method of treating lung cancer in a subject, the method comprising:
(a) determining the subtype of a lung sample obtained from the subject, wherein the lung sample is a squamous cell carcinoma lung cancer sample, wherein the determining the subtype comprises:
(i) measuring a nucleic acid expression level of each biomarker of a plurality of the biomarkers consisting of only SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R, PDZK1IP1, CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2, SPAG5, ME1, TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1, ALDH3A2, PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIMS, CD47, CRIP2, ST3GAL5, HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B, TTLL4, CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4, SDC1, FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5, ARL6IP5, ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2;
(ii) comparing the measured nucleic acid expression levels of each biomarker of the plurality of the biomarkers of (a)(i) in at least one sample training set(s), wherein the at least one sample training set is a reference lung squamous cell carcinoma primitive sample, a reference lung squamous cell carcinoma classical sample, a reference lung squamous cell carcinoma secretory sample, a reference lung squamous cell carcinoma basal sample or a combination thereof; and
(iii) classifying the subtype of lung squamous cell carcinoma as primitive, classical, secretory or basal based on the results of the comparing step; and
(b) administering a therapeutic agent based on the subtype of the lung squamous cell carcinoma, wherein a primitive subtype is administered an immunotherapeutic agent, while a classical, secretory or basal subtype is administered a chemotherapeutic agent or an angiogenesis inhibitor.

### Claim at position 10

-81. (canceled)

### Claim 82 (depends on 79)

The method of claim 79, wherein the lung sample was previously diagnosed as being a squamous cell carcinoma lung cancer sample.

### Claim at position 12

-91. (canceled)

### Claim 92 (depends on 79)

The method of claim 79, wherein the measuring the expression level is conducted using an amplification, hybridization and/or sequencing assay, wherein the amplification, hybridization and/or sequencing assay comprises performing quantitative real time reverse transcriptase polymerase chain reaction (qRT-PCR), RNAseq, microarrays, gene chips, nCounter Gene Expression Assay, Serial Analysis of Gene Expression (SAGE), Rapid Analysis of Gene Expression (RAGE), nuclease protection assays or Northern blotting.

### Claim at position 14

-94. (canceled)

### Claim 95 (depends on 79)

The method of claim 79, wherein the lung sample is a formalin-fixed, paraffin-embedded (FFPE) lung tissue sample, fresh or a frozen lung tissue sample, an exosome, wash fluids, cell pellets, or a bodily fluid obtained from the patient.

### Claim at position 16

-97. (canceled)

### Claim 98 (depends on 79)

The method of claim 79, wherein the immunotherapeutic agent is a checkpoint inhibitor.

### Claim at position 18

-105. (canceled)

### Claim 106 (depends on 28)

The method of claim 28, wherein the subset of biomarkers comprises ten (10) biomarkers, wherein the ten (10) biomarkers are selected from the groups consisting of (1) SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R and PDZK1IP1; (2) CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2 and SPAG5; (3) ME1, TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1 and ALDH3A2; (4) PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIM8, CD47, CRIP2 and ST3GAL5; (5) HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B and TTLL4; (6) CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4 and SDC1; (7) FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5 and ARL6IP5; and (8) ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2.

### Claim 107 (depends on 28)

The method of claim 28, wherein the subset of biomarkers comprises a group of twenty (20) biomarkers, wherein the group of twenty (20) biomarkers is selected from (1) SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R and PDZK1IP1, CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2 and SPAG5; (2) ME1, TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1 and ALDH3A2, PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIM8, CD47, CRIP2 and ST3GAL5; (3) HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B and TTLL4, CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4 and SDC1; (4) FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5 and ARL6IP5, ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2.

### Claim 108 (depends on 28)

The method of claim 28, further comprising measuring a nucleic acid expression level of the subset of biomarkers selected from the group of biomarkers consisting of SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R, PDZK1IP1, CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2, SPAG5, ME1, TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1, ALDH3A2, PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIM8, CD47, CRIP2, ST3GAL5, HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B, TTLL4, CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4, SDC1, FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5, ARL6IP5, ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2 in a normal lung sample, a basal sample, a classical sample, a secretory sample or a primitive SCC sample.

### Claim 109 (depends on 108)

The method of claim 108, wherein the subset of biomarkers comprises ten (10) biomarkers, wherein the ten (10) biomarkers are selected from the groups consisting of (1) SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R and PDZK1IP1; (2) CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2 and SPAG5; (3) ME1, TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1 and ALDH3A2; (4) PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIM8, CD47, CRIP2 and ST3GAL5; (5) HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B and TTLL4; (6) CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4 and SDC1; (7) FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5 and ARL6IP5; and (8) ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2.

### Claim 110 (depends on 108)

The method of claim 108, wherein the subset of biomarkers comprises twenty (20) biomarkers, wherein the group of twenty (20) biomarkers is selected from (1) SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R and PDZK1IP1, CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2 and SPAG5; (2) MEL TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1 and ALDH3A2, PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIMS, CD47, CRIP2 and ST3GAL5; (3) HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B and TTLL4, CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4 and SDC1; (4) FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5 and ARL6IP5, ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2.

### Claim 111 (depends on 79)

The method of claim 79, wherein further comprising comparing the measured nucleic acid expression levels of the subset of biomarkers to the nucleic acid expression levels of the subset of biomarkers in at least one sample training set(s), wherein the at least one sample training set is a reference lung squamous cell carcinoma basal sample, a reference lung squamous cell carcinoma classical sample, a reference lung squamous cell carcinoma secretory sample, a reference lung squamous cell carcinoma primitive sample or a combination thereof; and classifying the subtype of lung squamous cell carcinoma as basal, classical, secretory or primitive based on the results of the comparing step.

### Claim 112 (depends on 111)

The method of claim 111, wherein the comparing step comprises applying a statistical algorithm which comprises determining a correlation between the nucleic acid expression levels of the subset of biomarkers obtained from the lung sample and the nucleic acid expression levels of the subset of biomarkers from the at least one training set(s); and classifying the subtype of the lung squamous cell carcinoma as basal, classical, secretory or primitive based on the results of the statistical algorithm.

### Claim 113 (depends on 79)

The method of claim 79, wherein the subset of biomarkers comprises ten (10) biomarkers, wherein the ten (10) biomarkers are selected from the groups consisting of (1) SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R and PDZK1IP1; (2) CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2 and SPAG5; (3) MEL TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1 and ALDH3A2; (4) PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIMS, CD47, CRIP2 and ST3GAL5; (5) HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B and TTLL4; (6) CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4 and SDC1; (7) FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5 and ARL6IP5; and (8) ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2.

### Claim 114 (depends on 79)

The method of claim 79, wherein the subset of biomarkers comprises twenty (20) biomarkers, wherein the group of twenty (20) biomarkers is selected from (1) SERPINB4, CXCL1, S100A9, S100A8, SERPINB3, EPHA2, S100A2, MMP10, IL4R and PDZK1IP1, CDK5RAP2, FAM125B, CABC1, ODC1, LPIN1, WASF1, USP13, NUP210, GLI2 and SPAG5; (2) ME1, TALDO1, AKR1C3, TXN, ALDH3A1, CHST7, ADAM23, TUFT1, FOXE1 and ALDH3A2, PHC2, SLC43A3, CAPZB, FAM46A, PTP4A2, DPYD, TRIMS, CD47, CRIP2 and ST3GAL5; (3) HSF2, MARCKSL1, EFHD1, CHKA, PLEKHB1, FNBP1L, ZNF239, ABI2, MYL6B and TTLL4, CLCA2, GJB3, GPR87, SFN, CSTA, DSG3, ST6GALNAC2, GJB5, TMPRSS4 and SDC1; (4) FMNL1, BIRC3, ARHGDIB, SH2B3, HLA-DPA1, NCF4, ACSL5, CSF2RA, LAPTM5 and ARL6IP5, ADH7, ABCC5, SOX2, SLC9A3R1, KLF5, GPX2, PIR, TPD52L1, SLC6A8, and SIAH2.

### Claim 115 (depends on 98)

The method of claim 98, wherein the checkpoint inhibitor targets PD-1, PD-LI or CTLA-4.

### Claim 116 (depends on 98)

The method of claim 98, wherein the checkpoint inhibitor is a PD-1/PD-LI checkpoint inhibitor selected from the group consisting of nivolumab, pembrolizumab, atezolizumab, durvalumab, lambrolizumab, and avelumab or the checkpoint inhibitor is a CTLA-4 checkpoint inhibitor selected from ipilimumab and tremelimumab.
